MET as an Actionable Resistance Mechanism: New Randomized Data and What It Means

In this segment, the panel focuses on MET alterations as one of the most consistently actionable resistance mechanisms in EGFR-mutant non-small cell lung cancer and discusses the first randomized trial data now available in this setting. You will hear what the top-line results show about the benefit of targeting MET at progression, why this is an important proof of concept for treating resistance mechanisms prospectively, and what questions remain about the durability of response and the best patient selection criteria. The panel also addresses antibody-drug conjugates as an emerging option for patients without targetable resistance, covering both the promise of this class and the toxicity management considerations that community oncologists need to be prepared for, including pulmonary toxicity and ocular side effects.